James F Kronauge
Principal investigator.
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2005First federal award
$6.6MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $6.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2010 | NIH | SBIR/STTR Phase II A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec | $542K | — |
| Sep 17, 2010 | NIH | SBIR/STTR Phase I Development of a kit based PET molecular imaging agent: edotreotide Ga 68 for so | $263K | — |
| Sep 30, 2009 | NIH | SBIR/STTR Phase II Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta | $488K | — |
| Sep 30, 2009 | NIH | SBIR/STTR Phase II Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta | $327K | — |
| Sep 30, 2009 | NIH | SBIR/STTR Phase II Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta | $802K | — |
| Sep 16, 2008 | NIH | SBIR/STTR Phase II Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma | $912K | — |
| Sep 16, 2008 | NIH | SBIR/STTR Phase II Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma | $723K | — |
| Sep 16, 2008 | NIH | SBIR/STTR Phase II Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma | $331K | — |
| Aug 1, 2007 | NIH | SBIR/STTR Phase II Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals | $485K | — |
| Aug 1, 2007 | NIH | SBIR/STTR Phase II Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals | $131K | — |
| Aug 1, 2007 | NIH | SBIR/STTR Phase II Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals | $496K | — |
| Apr 1, 2005 | NIH | SBIR/STTR Phase I High sensitivity and low toxicity radiopharmaceuticals | $147K | — |
| Apr 1, 2005 | NIH | SBIR/STTR Phase II Developing Nanodosing of Iobenguane I 131 for Radiotherapy | $351K | — |
| Apr 1, 2005 | NIH | SBIR/STTR Phase II Developing Nanodosing of Iobenguane I 131 for Radiotherapy | $574K | — |
Peer ranks
Federal funding#39
Awards as PI#24
Patents#27
Companies
No tracked company linked yet.
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.